Insmed
INSM
141.33
-3.13
-2.17%
Insmed
US · INSM
#794 by market cap
Listed 1970
141.33
-3.13
-2.17%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
C
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Hold to Buy on 2026-03-30.
Analyst consensus 16 analysts
Buy
Avg price target 191.07 +35.2%
Price target rangecurrent 141.33
Low158.00
Avg191.07
High220.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-20 | BofA Securities | -- | Buy | 205.00 |
| 2026-11-19 | Mizuho Securities | -- | Buy | 158.00 |
| 2026-11-19 | Raymond James | -- | Buy | -- |
| 2026-11-19 | BofA Securities | -- | Buy | 205.00 |
| 2026-11-19 | Guggenheim | -- | Buy | 201.00 |
| 2026-11-17 | RBC Capital | -- | Buy | 195.00 |
| 2026-11-13 | Morgan Stanley | -- | Buy | 213.00 |
| 2026-11-05 | Evercore | -- | Buy | 170.00 |
| 2026-11-04 | H.C. Wainwright | -- | Buy | 220.00 |
| 2026-11-03 | Mizuho Securities | -- | Buy | 158.00 |
| 2026-11-02 | BMO Capital | -- | Buy | 192.00 |
| 2026-11-02 | Barclays | -- | Buy | 207.00 |
| 2026-11-01 | Guggenheim | -- | Buy | 201.00 |
| 2026-10-30 | UBS | -- | Buy | 172.00 |
| 2026-10-30 | Morgan Stanley | -- | Buy | 213.00 |
| 2026-10-30 | BMO Capital | -- | Buy | 192.00 |
| 2026-10-30 | Goldman Sachs | -- | Buy | 194.00 |
| 2026-10-29 | Mizuho Securities | -- | Buy | 154.00 |
| 2026-10-29 | Roth MKM | -- | Buy | 204.00 |
| 2026-10-29 | RBC Capital | -- | Buy | 195.00 |
| 2026-10-21 | Morgan Stanley | -- | Buy | 213.00 |
| 2026-10-20 | Raymond James | -- | Buy | 173.00 |
| 2026-10-20 | Roth MKM | -- | Buy | 198.00 |
| 2026-10-13 | Wells Fargo | -- | Buy | 169.00 |
| 2026-10-12 | Wolfe Research | -- | Hold | -- |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-30 | Morgan Stanley | Hold → Buy | 212.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | -- | ±15.78% | +15.07% (in line) |
| 2026/Q2 | 2026-08-06 | -- | ±13.43% | +33.86% (beat) |
| 2026/Q1 | 2026-05-07 | -- | ±11.12% | -23.41% (beat) |
| 2025/Q4 | 2026-02-19 | -- | ±6.53% | +6.54% (beat) |
| 2025/Q3 | 2025-10-30 | -- | ±9.58% | +16.33% (beat) |
| 2025/Q2 | 2025-08-07 | -- | ±11.27% | -1.76% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±12.74% | -3.88% (in line) |
| 2024/Q4 | 2025-02-20 | -- | ±6.45% | -0.26% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±9.82% | -4.29% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±10.20% | +1.16% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±21.80% | +1.46% (in line) |
| 2023/Q4 | 2024-02-22 | -- | ±11.03% | -3.86% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:34 · For reference only, not investment advice and not tailored to your situation.
Insmed discussion 0 comments